Developer docs
API playgroundTry for free, no card

Search company profiles

Prokaryotics

Full company profile

uuid0003jg5

Namestring
Prokaryotics
Legal namestring
Prokaryotics Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Prokaryotics Inc. is a privately held, discovery-stage biopharmaceutical company founded in 2017 as a spinout from Merck & Co., Inc. by a team of former senior Merck scientists including the head of that company's Antimicrobial Early Discovery Unit. The company is headquartered at the Institute for Life Science Entrepreneurship at Kean University in Union, New Jersey, and operates with a small team (approximately 1–10 personnel) focused exclusively on the discovery and early preclinical development of novel anti-infective agents.

The company's scientific platform targets bacterial cell envelope biogenesis, with particular emphasis on the outer membrane assembly machinery that Gram-negative bacteria use to resist antibiotic entry, as well as Gram-positive targets and antifungal programs against drug-resistant Candida, Aspergillus, and rare molds. The pipeline comprises multiple non-clinical programs: a β-lactam potentiation program (Tarocin) targeting wall teichoic acid biosynthesis to restore efficacy against MRSA; Gram-negative programs targeting MsbA-mediated lipopolysaccharide transport and the BamA β-barrel assembly complex; an Acinetobacter baumannii combination product pairing a bacterial cell wall inhibitor with polymyxin permeabilizers; and antifungal series targeting GPI cell wall biosynthesis. Two composition-of-matter and use patents have issued from the USPTO covering Tarocin adjuvants, and worldwide development and commercialization rights for the foundational assets were in-licensed from Merck, with additional compounds licensed from Fundación MEDINA and Northern Antibiotics.

The business model is asset-light and partnership-driven rather than commercial. Prokaryotics generates inflows from non-dilutive NIH/NIAID grant funding (cumulative $10M+ across twelve SBIR, R01, R21, and STTR awards between 2018 and 2025) and from licensing-related milestone payments and royalties under pharmaceutical partner agreements, most notably the January 2026 exclusive global license with Basilea Pharmaceutica for the broad-spectrum antifungal program carrying up to $48.5 million in potential milestone payments plus tiered royalties. Customers are effectively other pharmaceutical companies rather than end prescribers, and go-to-market is structured around advancing programs through preclinical proof-of-concept and then out-licensing clinical and commercial responsibility. Pamela Demain serves as CEO and Holly Sutterlin as President; Terry Roemer is Founder and CSO.

Short descriptiontext

Prokaryotics is a private, discovery-stage biopharmaceutical company spun out of Merck in 2017, developing novel antibacterial and antifungal drug candidates that target bacterial cell envelope biogenesis to overcome multidrug-resistant infections, and monetizing its preclinical pipeline through pharmaceutical licensing partnerships and NIH grants.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersUnion, United States
HQ citystring
Union
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
novel antibiotic discovery, antibacterial drug development, antifungal drug discovery, cell envelope targeting, biopharmaceutical research services
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antibiotic Drug Discovery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Prokaryotics generates revenue through licensing agreements with pharmaceutical partners, receiving upfront payments, development milestones, regulatory milestones, and commercial milestones. The Basilea partnership includes potential development, regulatory, and commercial milestone payments up to $48.5 million plus tiered royalties.

prokaryotics.com
2NIH Grant Funding
TypeProfessional Services
Description

Non-dilutive funding through NIH SBIR/STTR grants supporting various antibiotic and antifungal research programs. Multiple grants awarded including R01, R21, and SBIR Phase I/II awards totaling over $10 million historically.

prokaryotics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Prokaryotics is a discovery-stage biopharmaceutical company developing novel antibiotics and antifungals that target bacterial and fungal cell envelope biogenesis. The company licenses its preclinical drug programs to larger pharmaceutical partners (e.g., Basilea Pharmaceutica) for clinical development and commercialization, generating revenue through upfront payments, development/regulatory/commercial milestones, and tiered royalties. Its pipeline targets multidrug-resistant Gram-negative and Gram-positive bacteria (including MRSA, Acinetobacter baumannii) and drug-resistant fungal pathogens (Candida, Aspergillus, rare molds).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Targeting the global antibiotic resistance crisis projected to have health and economic impact rivaling global warming
Product overview1 text field

Prokaryotics is a privately-held biopharmaceutical company focused on the discovery and development of novel anti-infective drugs targeting antibiotic-resistant bacteria and fungi. The company emerged from licensing agreements with Merck & Co., Inc. and operates as an authentic antibacterial discovery organization. The product portfolio consists of multiple research and preclinical-stage programs targeting cell envelope biogenesis in both Gram-negative and Gram-positive bacteria, as well as antifungal programs. Key programs include: the Tarocin beta-lactam potentiation program (Phase 2, targeting MRSA), Gram-negative antibiotic programs targeting MsbA/LPS, the Acinetobacter baumannii combination product, the BamA inhibitor program, and antifungal programs including a broad-spectrum antifungal being developed in collaboration with Basilea Pharmaceutica. Prokaryotics leverages deep knowledge of bacterial physiology, innovative screening strategies, and medicinal chemistry expertise to develop next-generation antibiotics and antifungals.

Product and service2 records
1Antibiotic Discovery Programs - Cell Envelope Biogenesis
CategoryCore research programs
2Tarocin Beta-Lactam Potentiation Program
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Collaboration to jointly develop a first-in-class broad-spectrum antifungal for severe invasive infections caused by Candida, Aspergillus, and rare molds. Prokaryotics received undisclosed upfront payment and near-term milestones; potential total milestone payments up to USD 48.5 million plus tiered royalties. Basilea assumes responsibility for clinical development and global commercialization under exclusive global license.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Exclusive worldwide licensing agreement for new antibiotic compounds from the Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with CDI led by Dr. David Perlin, a leading infectious disease expert working on novel antibiotics to overcome drug-resistant bacteria.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Selected by AiCuris for its AiCubator initiative to support innovation in infectious disease. Prokaryotics' bacterial cell envelope-targeting antibiotic program was recognized as a novel and scientifically attractive resistance-breaking opportunity of high priority.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Located at ILSE at Kean University, providing access to research infrastructure and collaborative ecosystem for life science startups.

6INEOS Oxford
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership for antibiotic research collaboration.

prokaryotics.com
7SSG2
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic research partnership.

prokaryotics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration for infectious disease research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pre-clinical/clinical antifungal developer of fosmanogepix (acquired by Pfizer in 2021) — directly comparable to Prokaryotics' antifungal franchise in target (invasive fungal infections) and partnership-driven value creation.

TypeBroad incumbent
Description

Original licensor of Prokaryotics' foundational antibacterial programs and the global pharma from which the founding team spun out — comparable as a BROAD_INCUMBENT operating its own antibacterial discovery unit while serving as Prokaryotics' upstream IP partner.

TypeDirect peer
Description

Clinical/commercial antifungal developer of ibrexafungerp (BREXAFEMME), which was originally designed by Prokaryotics' Director of Chemistry R. Wilkening at Merck — making Scynexis the closest direct comparable to Prokaryotics' antifungal programs in target class and strategic model.

TypeDirect peer
Description

Clinical-stage anti-infective company developing antifungal and antibacterial drug-Fc conjugates (e.g., rezafungin) — directly comparable to Prokaryotics as a small-cap anti-infective biotech pursuing novel mechanisms against drug-resistant pathogens.

TypeDirect peer
Description

Private clinical-stage antibiotic developer with programs targeting ESBL-producing Gram-negative bacteria and other resistant pathogens — directly comparable in pre-commercial antibiotic discovery model and partnering-oriented GTM.

TypeDirect peer
Description

Clinical-stage anti-infective company developing oral sulopenem for multidrug-resistant Gram-negative infections — directly comparable as a small-cap pharma focused on antibiotic-resistant pathogens.

TypeDirect peer
Description

Swiss privately-held clinical-stage antibacterial company developing small molecules to overcome drug resistance via potentiators and direct-acting antibiotics — closely comparable to Prokaryotics' potentiation (Tarocin) and novel mechanism approach.

TypeDirect peer
Description

Clinical-stage antibiotic developer with a DNA polymerase IIIC inhibitor (ibezapolstat) targeting C. difficile and Gram-positive infections — comparable as a small-cap pre-revenue antibacterial biotech with partner-driven commercialization.

TypeDirect peer
Description

French privately-held early-stage antibiotic company discovering novel classes from microbial biodiversity — directly comparable to Prokaryotics as a small-cap antibacterial R&D platform pursuing new mechanisms against resistant bacteria.

TypeDirect peer
Description

Antibiotic developer (Baxdela, Orbactiv, Kimyrsa) that emerged from Chapter 11 and remains a small-cap broad-spectrum antibiotic company — directly comparable as a commercial/clinical-stage antibacterial company despite financial distress history.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prokaryotics

Antibiotic Drug Discoveryprokaryotics.com

Prokaryotics is a private, discovery-stage biopharmaceutical company spun out of Merck in 2017, developing novel antibacterial and antifungal drug candidates that target bacterial cell envelope biogenesis to overcome multidrug-resistant infections, and monetizing its preclinical pipeline through pharmaceutical licensing partnerships and NIH grants.

What Prokaryotics does

Prokaryotics Inc. is a privately held, discovery-stage biopharmaceutical company founded in 2017 as a spinout from Merck & Co., Inc. by a team of former senior Merck scientists including the head of that company's Antimicrobial Early Discovery Unit. The company is headquartered at the Institute for Life Science Entrepreneurship at Kean University in Union, New Jersey, and operates with a small team (approximately 1–10 personnel) focused exclusively on the discovery and early preclinical development of novel anti-infective agents.

The company's scientific platform targets bacterial cell envelope biogenesis, with particular emphasis on the outer membrane assembly machinery that Gram-negative bacteria use to resist antibiotic entry, as well as Gram-positive targets and antifungal programs against drug-resistant Candida, Aspergillus, and rare molds. The pipeline comprises multiple non-clinical programs: a β-lactam potentiation program (Tarocin) targeting wall teichoic acid biosynthesis to restore efficacy against MRSA; Gram-negative programs targeting MsbA-mediated lipopolysaccharide transport and the BamA β-barrel assembly complex; an Acinetobacter baumannii combination product pairing a bacterial cell wall inhibitor with polymyxin permeabilizers; and antifungal series targeting GPI cell wall biosynthesis. Two composition-of-matter and use patents have issued from the USPTO covering Tarocin adjuvants, and worldwide development and commercialization rights for the foundational assets were in-licensed from Merck, with additional compounds licensed from Fundación MEDINA and Northern Antibiotics.

The business model is asset-light and partnership-driven rather than commercial. Prokaryotics generates inflows from non-dilutive NIH/NIAID grant funding (cumulative $10M+ across twelve SBIR, R01, R21, and STTR awards between 2018 and 2025) and from licensing-related milestone payments and royalties under pharmaceutical partner agreements, most notably the January 2026 exclusive global license with Basilea Pharmaceutica for the broad-spectrum antifungal program carrying up to $48.5 million in potential milestone payments plus tiered royalties. Customers are effectively other pharmaceutical companies rather than end prescribers, and go-to-market is structured around advancing programs through preclinical proof-of-concept and then out-licensing clinical and commercial responsibility. Pamela Demain serves as CEO and Holly Sutterlin as President; Terry Roemer is Founder and CSO.

Prokaryotics firmographics

Firmographics
Name
Prokaryotics
Legal name
Prokaryotics Inc.
Website
https://prokaryotics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Prokaryotics is a private, discovery-stage biopharmaceutical company spun out of Merck in 2017, developing novel antibacterial and antifungal drug candidates that target bacterial cell envelope biogenesis to overcome multidrug-resistant infections, and monetizing its preclinical pipeline through pharmaceutical licensing partnerships and NIH grants.
Ownership category
akta.pro rank

Prokaryotics industry classification

Industry
Product category
Antibiotic Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Novel antibiotic discovery
  • Antibacterial drug development
  • Antifungal drug discovery
  • Cell envelope targeting
  • Biopharmaceutical research services

Where Prokaryotics is headquartered

Location

Headquarters

HQ city
Union
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Prokaryotics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

  1. Licensing and Milestone Payments: Prokaryotics generates revenue through licensing agreements with pharmaceutical partners, receiving upfront payments, development milestones, regulatory milestones, and commercial milestones. The Basilea partnership includes potential development, regulatory, and commercial milestone payments up to $48.5 million plus tiered royalties.
  2. NIH Grant Funding: Non-dilutive funding through NIH SBIR/STTR grants supporting various antibiotic and antifungal research programs. Multiple grants awarded including R01, R21, and SBIR Phase I/II awards totaling over $10 million historically.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Prokaryotics product offering

Product offering

Core offering

Prokaryotics is a discovery-stage biopharmaceutical company developing novel antibiotics and antifungals that target bacterial and fungal cell envelope biogenesis. The company licenses its preclinical drug programs to larger pharmaceutical partners (e.g., Basilea Pharmaceutica) for clinical development and commercialization, generating revenue through upfront payments, development/regulatory/commercial milestones, and tiered royalties. Its pipeline targets multidrug-resistant Gram-negative and Gram-positive bacteria (including MRSA, Acinetobacter baumannii) and drug-resistant fungal pathogens (Candida, Aspergillus, rare molds).

Product overview

Prokaryotics is a privately-held biopharmaceutical company focused on the discovery and development of novel anti-infective drugs targeting antibiotic-resistant bacteria and fungi. The company emerged from licensing agreements with Merck & Co., Inc. and operates as an authentic antibacterial discovery organization. The product portfolio consists of multiple research and preclinical-stage programs targeting cell envelope biogenesis in both Gram-negative and Gram-positive bacteria, as well as antifungal programs. Key programs include: the Tarocin beta-lactam potentiation program (Phase 2, targeting MRSA), Gram-negative antibiotic programs targeting MsbA/LPS, the Acinetobacter baumannii combination product, the BamA inhibitor program, and antifungal programs including a broad-spectrum antifungal being developed in collaboration with Basilea Pharmaceutica. Prokaryotics leverages deep knowledge of bacterial physiology, innovative screening strategies, and medicinal chemistry expertise to develop next-generation antibiotics and antifungals.

Differentiator

Problem solved

Functional benefit

Products and services

  • Antibiotic Discovery Programs - Cell Envelope Biogenesis
  • Tarocin Beta-Lactam Potentiation Program

Quantifiable outcome

  • Targeting the global antibiotic resistance crisis projected to have health and economic impact rivaling global warming

Companies that use Prokaryotics

Customer profile

Segments2 records

Ideal customer profiles2 records

Prokaryotics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Prokaryotics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, major, notable and minor.

  • Basilea Pharmaceutica LtdcoreStrategic or Co-development Partner · 7 January 2026Collaboration to jointly develop a first-in-class broad-spectrum antifungal for severe invasive infections caused by Candida, Aspergillus, and rare molds. Prokaryotics received undisclosed upfront payment and near-term milestones; potential total milestone payments up to USD 48.5 million plus tiered royalties. Basilea assumes responsibility for clinical development and global commercialization under exclusive global license.
  • Fundación MEDINAmajorStrategic or Co-development PartnerExclusive worldwide licensing agreement for new antibiotic compounds from the Spanish foundation Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucia.
  • Hackensack Meridian Health - Center for Discovery and Innovation (CDI)majorStrategic or Co-development PartnerCollaboration with CDI led by Dr. David Perlin, a leading infectious disease expert working on novel antibiotics to overcome drug-resistant bacteria.
  • AiCuris Anti-infective Cures AGnotableStrategic or Co-development PartnerSelected by AiCuris for its AiCubator initiative to support innovation in infectious disease. Prokaryotics' bacterial cell envelope-targeting antibiotic program was recognized as a novel and scientifically attractive resistance-breaking opportunity of high priority.
  • Institute for Life Science Entrepreneurship (ILSE)majorStrategic or Co-development PartnerLocated at ILSE at Kean University, providing access to research infrastructure and collaborative ecosystem for life science startups.
  • INEOS OxfordminorStrategic or Co-development PartnerAcademic partnership for antibiotic research collaboration.
  • SSG2minorStrategic or Co-development PartnerStrategic research partnership.
  • University of FloridaminorStrategic or Co-development PartnerAcademic collaboration for infectious disease research.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Prokaryotics competitors and assessment

Company assessment

Direct peers

  • Amplyx Pharmaceuticals: Pre-clinical/clinical antifungal developer of fosmanogepix (acquired by Pfizer in 2021) — directly comparable to Prokaryotics' antifungal franchise in target (invasive fungal infections) and partnership-driven value creation.
  • Scynexis: Clinical/commercial antifungal developer of ibrexafungerp (BREXAFEMME), which was originally designed by Prokaryotics' Director of Chemistry R. Wilkening at Merck — making Scynexis the closest direct comparable to Prokaryotics' antifungal programs in target class and strategic model.
  • Cidara Therapeutics: Clinical-stage anti-infective company developing antifungal and antibacterial drug-Fc conjugates (e.g., rezafungin) — directly comparable to Prokaryotics as a small-cap anti-infective biotech pursuing novel mechanisms against drug-resistant pathogens.
  • VenatoRx Pharmaceuticals: Private clinical-stage antibiotic developer with programs targeting ESBL-producing Gram-negative bacteria and other resistant pathogens — directly comparable in pre-commercial antibiotic discovery model and partnering-oriented GTM.
  • Iterum Therapeutics: Clinical-stage anti-infective company developing oral sulopenem for multidrug-resistant Gram-negative infections — directly comparable as a small-cap pharma focused on antibiotic-resistant pathogens.
  • BioVersys: Swiss privately-held clinical-stage antibacterial company developing small molecules to overcome drug resistance via potentiators and direct-acting antibiotics — closely comparable to Prokaryotics' potentiation (Tarocin) and novel mechanism approach.
  • Acurx Pharmaceuticals: Clinical-stage antibiotic developer with a DNA polymerase IIIC inhibitor (ibezapolstat) targeting C. difficile and Gram-positive infections — comparable as a small-cap pre-revenue antibacterial biotech with partner-driven commercialization.
  • Nosopharm: French privately-held early-stage antibiotic company discovering novel classes from microbial biodiversity — directly comparable to Prokaryotics as a small-cap antibacterial R&D platform pursuing new mechanisms against resistant bacteria.
  • Melinta Therapeutics: Antibiotic developer (Baxdela, Orbactiv, Kimyrsa) that emerged from Chapter 11 and remains a small-cap broad-spectrum antibiotic company — directly comparable as a commercial/clinical-stage antibacterial company despite financial distress history.

Broad incumbents

  • Merck & Co., Inc. Original licensor of Prokaryotics' foundational antibacterial programs and the global pharma from which the founding team spun out — comparable as a BROAD_INCUMBENT operating its own antibacterial discovery unit while serving as Prokaryotics' upstream IP partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Prokaryotics social profiles

Digital presence

Prokaryotics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prokaryotics leadership team

Management profile

Number of profiles

Profiles10 records

Prokaryotics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prokaryotics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prokaryotics

What does Prokaryotics do?

Prokaryotics is a discovery-stage biopharmaceutical company developing novel antibiotics and antifungals that target bacterial and fungal cell envelope biogenesis. The company licenses its preclinical drug programs to larger pharmaceutical partners (e.g., Basilea Pharmaceutica) for clinical development and commercialization, generating revenue through upfront payments, development/regulatory/commercial milestones, and tiered royalties. Its pipeline targets multidrug-resistant Gram-negative and Gram-positive bacteria (including MRSA, Acinetobacter baumannii) and drug-resistant fungal pathogens (Candida, Aspergillus, rare molds).

Is Prokaryotics a public or private company?

Prokaryotics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Prokaryotics founded?

Prokaryotics was founded in 2017. It employs 1 to 10 people.

Where is Prokaryotics based?

Prokaryotics is headquartered in Union, United States, in the North America region.

How does Prokaryotics make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are NIH Grant Funding.

Who are Prokaryotics's main competitors?

Direct peers on record are Amplyx Pharmaceuticals, Scynexis, Cidara Therapeutics, VenatoRx Pharmaceuticals, Iterum Therapeutics, BioVersys, Acurx Pharmaceuticals, Nosopharm and Melinta Therapeutics. Merck & Co., Inc. is listed as a broad incumbent.

Does Prokaryotics have an API?

No public API is recorded for Prokaryotics.

What industry is Prokaryotics in?

Prokaryotics's product category is Antibiotic Drug Discovery. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechBasilea pens collab with US biotech to develop new antifungalBasilea Pharmaceutica and Prokaryotics have formed a collaboration to develop a new broad-spectrum antifungal for invasive infections, with Basilea taking lead on further development after candidate identification. The partnership involves undisclosed upfront payment and milestone payments potentially totaling up to $48.5 million, along with royalties if the drug reaches market.PR NewswireProkaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infectionsProkaryotics Inc. and Basilea Pharmaceutica Ltd announced a collaboration to jointly develop a first-in-class broad-spectrum antifungal for severe invasive infections caused by Candida, Aspergillus, and rare molds. Under the terms, Basilea will make an undisclosed upfront payment and near-term milestones to Prokaryotics, with potential development, regulatory, and commercial milestone payments up to USD 48.5 million plus tiered royalties, while Basilea assumes responsibility for clinical development and global commercialization under an exclusive global license. The partnership addresses a critical unmet medical need as serious fungal infections cause approximately 1.7 million deaths worldwide annually, with increasing resistance to existing antifungal drugs.PR NewswireProkaryotics Announces Licensing Agreement with Northern Antibiotics for Novel Gram-negative Antibiotic PotentiatorProkaryotics Inc. announced on June 26, 2025, that it entered into a licensing agreement with Northern Antibiotics on June 4, 2025, gaining worldwide rights to develop, manufacture, and commercialize NAB741, a Gram-negative antibiotic potentiator designed to increase bacterial membrane permeability. NAB741 successfully completed first-in-human Phase 1 clinical trials demonstrating favorable safety, tolerability, and pharmacokinetics. Prokaryotics plans to combine NAB741 with its own novel antibiotic lead classes to develop fixed-dose combination agents for treating antibiotic-resistant infections.Pocket-lintGoogle 3D objects: How to view dinosaurs in AR right in your kitchenGoogle offers augmented reality 3D objects in Search, such as dinosaurs, viewable via mobile devices. Users search for an item, tap 'View in 3D,' then 'View in your space' to see it in their environment. Requirements include Android 7+ with ARCore or iOS 11+ on iPhone/iPad.PR NewswireProkaryotics Receives $2.3 Million SBIR Award Supporting Its Immune Potentiation Program and Advances Two Additional SBIR-funded Antibiotic Programs into Phase 2 Lead OptimizationProkaryotics, Inc. has been awarded a $2.3 million Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to fund its immune potentiation program targeting antimicrobial resistant Gram-negative bacteria over three years. The first phase will receive $295,541 for mechanism of action and bacterial spectrum studies, with Phase 2 funding of nearly $2.0 million contingent on success to support lead optimization and in vivo efficacy studies. The company has also advanced two additional SBIR-funded programs targeting MRSA and multi-drug resistant Neisseria gonorrhoeae into Phase 2 lead optimization.PR NewswireProkaryotics Announces Exclusive Worldwide Licensing Agreement with MEDINA for New Antibiotic CompoundsProkaryotics, Inc. announced it has entered into an exclusive worldwide licensing agreement with Fundación MEDINA, a not-for-profit Spanish foundation, to develop, manufacture, and commercialize a novel natural product-based antibiotic class with a new mechanism of action targeting bacterial cell wall biosynthesis. Prokaryotics gains global rights to these antibiotic compounds discovered from MEDINA's natural product libraries, with MEDINA eligible for royalty payments on any resulting products; specific terms were not disclosed. The partnership combines MEDINA's drug discovery expertise with Prokaryotics' clinical development capabilities to address the urgent global need for new antibiotics against multi-drug resistant bacteria.PR NewswireProkaryotics Receives $2.3 Million SBIR Grant Supporting A Second Novel Antibiotic ProgramProkaryotics, Inc. has been awarded a second Small Business Innovation Research (SBIR) grant valued at up to $2.3 million from the National Institute of Allergy and Infectious Diseases (NIAID). The funding will support research on a novel antibiotic targeting antimicrobial-resistant Neisseria gonorrhoeae, with initial funds allocated for natural product isolation and subsequent funds for pre-clinical studies. This non-dilutive capital enables Prokaryotics to advance its antibacterial programs prior to raising substantial Series A financing.PR NewswireProkaryotics Receives $2.5 Million SBIR Grant to Support Novel Antibiotic ProgramProkaryotics, Inc. has been awarded a Small Business Innovation Research (SBIR) grant of up to $2.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to fund research on restoring beta-lactam antibiotic efficacy against methicillin-resistant Staphylococci (MRSA). The two-year grant begins with a first phase of $299,999, with contingent second phase funding of $2.2 million dependent on achieving pre-clinical candidate selection. This grant follows Prokaryotics' January 2018 exclusive license agreement with Merck for novel antibiotic candidates.PR NewswireProkaryotics Announces Licensing Agreement with Merck for Novel Investigational Antibiotic CandidatesProkaryotics, Inc., a privately-held biopharmaceutical company based in Union, New Jersey, has entered into a licensing agreement with Merck (known as MSD outside the United States and Canada) for novel investigational antibiotic candidates. Under the agreement, Prokaryotics gains worldwide rights to develop, manufacture, and commercialize early pre-clinical programs targeting Gram-negative and Gram-positive bacterial cell envelope enzymes, with specific terms remaining undisclosed. The deal supports Prokaryotics' position in addressing the growing global threat of antibiotic resistance, with the company leveraging its academic network to advance the assets.